Lantern Pharma (NASDAQ: LTRN) has reported its second-quarter 2026 operational and financial results, highlighting significant progress in its AI-driven oncology pipeline and the strategic establishment of Open Medicine AI (“OMAI”) as a separate company. The company's focus on precision oncology and its proprietary RADR® platform continues to yield promising developments.
Emerging data from the Phase 2 HARMONIC™ trial revealed that LP-300's progression-free survival benefit deepened with treatment duration in patients with EGFR exon 21 L858R mutations. The FDA reviewed key protocol amendments without objection, signaling a favorable regulatory environment for the trial's advancement. Additionally, the European Medicines Agency cleared an investigator-initiated Phase 1b/2 trial of LP-184, also known as zirdafulven, in biomarker-selected advanced bladder cancer. In a further boost, the U.S. Patent and Trademark Office issued a Notice of Allowance covering a three-gene patient-selection signature for LP-184, potentially enhancing the drug's precision targeting.
In August, Lantern took a major strategic step by establishing OMAI as a wholly owned subsidiary and entering into board-approved commercial licensing agreements for the multi-agentic AI co-scientist platform previously launched as withZeta.ai. This move aims to unlock value from its AI capabilities and create a new revenue stream for the company.
Financially, Lantern reported a second-quarter loss from operations of approximately $3.5 million, down about 25% from $4.7 million in the same period last year. R&D expenses declined 42% to approximately $1.8 million, reflecting efficient capital management. However, the net loss was approximately $7.1 million, or $0.57 per share, compared with $4.3 million, or $0.40 per share, a year earlier. The increase was largely due to approximately $3.6 million in warrant-related expense. As of June 30, 2026, cash, cash equivalents, and marketable securities totaled approximately $7.4 million.
These results underscore Lantern's commitment to advancing its pipeline while strategically aligning its AI assets through OMAI. The establishment of OMAI as a separate entity could attract dedicated investment and partnerships, potentially accelerating the development and commercialization of its AI co-scientist platform. For investors, the deepening efficacy data for LP-300 and regulatory progress for LP-184 are positive signals, though the company's cash position remains a consideration for future funding needs.
Lantern Pharma continues to leverage its AI and machine learning capabilities through its RADR® platform to transform cancer therapy development. The company's pipeline includes LP-184, LP-284, and LP-300, with LP-300 being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, a wholly owned CNS-focused subsidiary. The withZeta.ai platform is now commercially available as a subscription-based research platform, representing a new revenue stream.
The company operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas. For more details, visit the full press release at https://nnw.fm/m9pULA.
